

For Immediate Release

**Q4 Net Revenue grew 15% to Rs 853 Crores, Net Profit at Rs 93 cr
Vadodara May 16th, 2018**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the fourth quarter ending 31st March 2018.

Financial Highlights

- Net Sales for the quarter up 15% to Rs 853 crores
- Net Profit for the quarter at Rs 93 crores against Rs 92 crores last year.
- FY18 Net sales at Rs 3131 crores as against Rs 3134 crores last year.
- Net Profit for the year at Rs 409 crores against Rs 399 crores last year.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “ I am happy to note that we grew the US Generic Business by 45% during the quarter despite a challenging and dynamic business environment”

Operational Highlights

International Business

- International formulation business grew 29% to Rs 352 crores for the quarter
- US Generics grew 45% to Rs 290 crores for the quarter
- The Panelav API 1 & API 2 facilities were audited by the US FDA without any observations,
- The Formulation facility at Panelav was audited by the USFDA with three form 483 observations
- 13 ANDA approvals (Including 4 tentative) received during the year, Cumulative ANDA approvals at 70 (Including 9 tentative)
- 12 ANDA filings (including Aleor JV) during the quarter and 26 ANDA filings (including Aleor JV) for FY18
- Cumulative ANDA filings at 132
- FY18 R&D spend at Rs 411 Crores, approximately 13% of Sales.



ALEMBIC PHARMACEUTICALS LIMITED

India Formulations Business

- India formulations business for the quarter at Rs 304 crores as against Rs 287 crores last year
- India formulations business for the year at Rs 1274 crores as against Rs 1254 crores last year (not strictly comparable due to GST accounting effect)

Dividend

- The Board has recommended dividend on equity shares at Rs 4.00 per share i.e. 200% for 17-18 (P.Y. Rs 4.00 per share i.e. 200%).

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q4 FY18	Q4 FY17	FY18	FY17
International Formulation	352	273	1206	1237
<i>USA</i>	<i>290</i>	<i>200</i>	<i>920</i>	<i>919</i>
<i>ROW</i>	<i>62</i>	<i>73</i>	<i>286</i>	<i>318</i>
India Formulations	304	287	1274	1254
API	198	181	651	643
Total	853	741	3131	3134



ALEMBIC PHARMACEUTICALS LIMITED

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q4 FY18	Q4 FY17	FY18	FY17
EBITDA Pre R&D	281	242	1036	1027
<i>EBITDA Pre R&D %</i>	33%	33%	33%	33%
EBITDA Post R&D	165	133	642	613
<i>EBITDA Post R&D %</i>	19%	18%	21%	20%
Profit Before Tax	132	110	533	525
Net Profit after Tax	93	92	409	399

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123